Adaptive TCR has changed its name to Adaptive Biotechnologies, the company said this week.

The Seattle-based firm provides next-generation sequencing assays under the brand name ImmunoSeq to analyze the adaptive immune system.

Last summer, it raised $5.8 million in a Series B round to grow its services and invest in clinical applications (CSN 6/15/2011).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.